Skip to main content
PMC home page
Medline Book to support NIHPA logoLink to Medline Book to support NIHPA
. 2020 Jun;24(27):1–90. doi: 10.3310/hta24270

Sodium bicarbonate to improve physical function in patients over 60 years with advanced chronic kidney disease: the BiCARB RCT.

Miles D Witham, Margaret Band, Huey Chong, Peter T Donnan, Geeta Hampson, May Khei Hu, Roberta Littleford, Edmund Lamb, Philip A Kalra, Gwen Kennedy, Paul McNamee, Deirdre Plews, Petra Rauchhaus, Roy L Soiza, Deepa Sumukadas, Graham Warwick, Alison Avenell
PMCID: PMC7336221  PMID: 32568065

Abstract

BACKGROUND

Advanced chronic kidney disease is common in older people and is frequently accompanied by metabolic acidosis. Oral sodium bicarbonate is used to treat this acidosis, but evidence is lacking on whether or not this provides a net gain in health or quality of life for older people.

OBJECTIVES

The objectives were to determine whether or not oral bicarbonate therapy improves physical function, quality of life, markers of renal function, bone turnover and vascular health compared with placebo in older people with chronic kidney disease and mild acidosis; to assess the safety of oral bicarbonate; and to establish whether or not oral bicarbonate therapy is cost-effective in this setting.

DESIGN

A parallel-group, double-blind, placebo-controlled randomised trial.

SETTING

The setting was nephrology and geriatric medicine outpatient departments in 27 UK hospitals.

PARTICIPANTS

Participants were adults aged ≥ 60 years with advanced chronic kidney disease (glomerular filtration rate category 4 or 5, not on dialysis) with a serum bicarbonate concentration of < 22 mmol/l.

INTERVENTIONS

Eligible participants were randomised 1 : 1 to oral sodium bicarbonate or matching placebo. Dosing started at 500 mg three times daily, increasing to 1 g three times daily if the serum bicarbonate concentration was < 22 mmol/l at 3 months.

MAIN OUTCOME MEASURES

The primary outcome was the between-group difference in the Short Physical Performance Battery score at 12 months, adjusted for baseline. Other outcome measures included generic and disease-specific health-related quality of life, anthropometry, 6-minute walk speed, grip strength, renal function, markers of bone turnover, blood pressure and brain natriuretic peptide. All adverse events were recorded, including commencement of renal replacement therapy. For the health economic analysis, the incremental cost per quality-adjusted life-year was the main outcome.

RESULTS

In total, 300 participants were randomised, 152 to bicarbonate and 148 to placebo. The mean age of participants was 74 years and 86 (29%) were female. Adherence to study medication was 73% in both groups. A total of 220 (73%) participants were assessed at the 12-month visit. No significant treatment effect was evident for the primary outcome of the between-group difference in the Short Physical Performance Battery score at 12 months (-0.4 points, 95% confidence interval -0.9 to 0.1 points; p = 0.15). No significant treatment benefit was seen for any of the secondary outcomes. Adverse events were more frequent in the bicarbonate arm (457 vs. 400). Time to commencement of renal replacement therapy was similar in both groups (hazard ratio 1.22, 95% confidence interval 0.74 to 2.02; p = 0.43). Health economic analysis showed higher costs and lower quality of life in the bicarbonate arm at 1 year, with additional costs of £564 (95% confidence interval £88 to £1154) and a quality-adjusted life-year difference of -0.05 (95% confidence interval -0.08 to -0.01); placebo dominated bicarbonate under all sensitivity analyses for incremental cost-effectiveness.

LIMITATIONS

The trial population was predominantly white and male, limiting generalisability. The increment in serum bicarbonate concentrations achieved was small and a benefit from larger doses of bicarbonate cannot be excluded.

CONCLUSIONS

Oral sodium bicarbonate did not improve a range of health measures in people aged ≥ 60 years with chronic kidney disease category 4 or 5 and mild acidosis, and is unlikely to be cost-effective for use in the NHS in this patient group. Once other current trials of bicarbonate therapy in chronic kidney disease are complete, an individual participant meta-analysis would be helpful to determine which subgroups, if any, are more likely to benefit and which treatment regimens are more beneficial.

TRIAL REGISTRATION

Current Controlled Trials ISRCTN09486651 and EudraCT 2011-005271-16. The systematic review is registered as PROSPERO CRD42018112908.

FUNDING

This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 27. See the NIHR Journals Library website for further project information.

Plain language summary

Patients with advanced chronic kidney disease often have excessive levels of acid in their blood (acidosis). Acidosis has been associated with a range of other problems that particularly affect patients with chronic kidney disease, including weaker muscles, weaker bones, worse blood vessel health and kidney disease that worsens more quickly. For decades, acidosis has been treated with sodium bicarbonate tablets (the ingredient found in baking soda) to neutralise the excess acid. However, sodium bicarbonate is awkward to take, may cause side effects and may increase blood pressure. To clarify whether or not sodium bicarbonate caused an overall improvement in health, we carried out a study involving 300 people aged ≥ 60 years with advanced chronic kidney disease and mild acidosis. Half received sodium bicarbonate capsules and half received dummy capsules (placebo), for up to 2 years. The treatments were chosen randomly by a computer and the participants, their doctors and the researchers were not aware of the treatment received until the end of the study. We measured physical function (walking speed, ability to stand from a chair, balance) alongside quality of life, kidney function, bone and blood vessel health, side effects and health service use over 2 years. We found that sodium bicarbonate did not improve physical function or quality of life compared with placebo. Sodium bicarbonate also did not improve kidney function, bone health or blood vessel health compared with placebo. More people in the sodium bicarbonate group than in the placebo group had side effects, although blood pressure was the same in both groups. Health-care costs were higher in the sodium bicarbonate group than in the placebo group. We conclude that oral sodium bicarbonate did not significantly improve health measures compared with placebo for older people (aged ≥ 60 years) with advanced chronic kidney disease associated with mild acidosis.

Full text of this article can be found in Bookshelf.

References

  1. Public Health England. Chronic Kidney Disease Prevalence Model. London: Public Health England; 2015. URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/612303/ChronickidneydiseaseCKDprevalencemodelbriefing.pdf (accessed 6 January 2019).
  2. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1–12. https://doi.org/10.1053/ajkd.2003.50007 doi: 10.1053/ajkd.2003.50007. [DOI] [PubMed]
  3. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038–47. https://doi.org/10.1001/jama.298.17.2038 doi: 10.1001/jama.298.17.2038. [DOI] [PubMed]
  4. Eustace JA, Astor B, Muntner PM, Ikizler TA, Coresh J. Prevalence of acidosis and inflammation and their association with low serum albumin in chronic kidney disease. Kidney Int 2004;65:1031–40. https://doi.org/10.1111/j.1523-1755.2004.00481.x doi: 10.1111/j.1523-1755.2004.00481.x. [DOI] [PubMed]
  5. Menon V, Tighiouart H, Vaughn NS, Beck GJ, Kusek JW, Collins AJ, et al. Serum bicarbonate and long-term outcomes in CKD. Am J Kidney Dis 2010;56:907–14. https://doi.org/10.1053/j.ajkd.2010.03.023 doi: 10.1053/j.ajkd.2010.03.023. [DOI] [PubMed]
  6. Goldenstein L, Driver TH, Fried LF, Rifkin DE, Patel KV, Yenchek RH, et al. Serum bicarbonate concentrations and kidney disease progression in community-living elders: the Health, Aging, and Body Composition (Health ABC) Study. Am J Kidney Dis 2014;64:542–9. https://doi.org/10.1053/j.ajkd.2014.05.009 doi: 10.1053/j.ajkd.2014.05.009. [DOI] [PMC free article] [PubMed]
  7. Schutte E, Lambers Heerspink HJ, Lutgers HL, Bakker SJ, Vart P, Wolffenbuttel BH, et al. Serum bicarbonate and kidney disease progression and cardiovascular outcome in patients with diabetic nephropathy: a post hoc analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) study and IDNT (Irbesartan Diabetic Nephropathy Trial). Am J Kidney Dis 2015;66:450–8. https://doi.org/10.1053/j.ajkd.2015.03.032 doi: 10.1053/j.ajkd.2015.03.032. [DOI] [PubMed]
  8. Driver TH, Shlipak MG, Katz R, Goldenstein L, Sarnak MJ, Hoofnagle AN, et al. Low serum bicarbonate and kidney function decline: the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis 2014;64:534–41. https://doi.org/10.1053/j.ajkd.2014.05.008 doi: 10.1053/j.ajkd.2014.05.008. [DOI] [PMC free article] [PubMed]
  9. Wesson DE, Simoni J, Broglio K, Sheather S. Acid retention accompanies reduced GFR in humans and increases plasma levels of endothelin and aldosterone. Am J Physiol Renal Physiol 2011;300:F830–7. https://doi.org/10.1152/ajprenal.00587.2010 doi: 10.1152/ajprenal.00587.2010. [DOI] [PubMed]
  10. Kendrick J, Shah P, Andrews E, You Z, Nowak K, Pasch A, Chonchol M. Effect of treatment of metabolic acidosis on vascular endothelial function in patients with CKD: a pilot randomized cross-over study. Clin J Am Soc Nephrol 2018;13:1463–70. https://doi.org/10.2215/CJN.00380118 doi: 10.2215/CJN.00380118. [DOI] [PMC free article] [PubMed]
  11. Kraut JA, Madias NE. Adverse effects of the metabolic acidosis of chronic kidney disease. Adv Chronic Kidney Dis 2017;24:289–97. https://doi.org/10.1053/j.ackd.2017.06.005 doi: 10.1053/j.ackd.2017.06.005. [DOI] [PubMed]
  12. Dobre M, Yang W, Chen J, Drawz P, Hamm LL, Horwitz E, et al. Association of serum bicarbonate with risk of renal and cardiovascular outcomes in CKD: a report from the Chronic Renal Insufficiency Cohort (CRIC) study. Am J Kidney Dis 2013;62:670–8. https://doi.org/10.1053/j.ajkd.2013.01.017 doi: 10.1053/j.ajkd.2013.01.017. [DOI] [PMC free article] [PubMed]
  13. Clegg DJ, Cody M, Palmer BF. Challenges in treating cardiovascular disease: restricting sodium and managing hyperkalemia. Mayo Clin Proc 2017;92:1248–60. https://doi.org/10.1016/j.mayocp.2017.04.006 doi: 10.1016/j.mayocp.2017.04.006. [DOI] [PubMed]
  14. Abramowitz MK, Hostetter TH, Melamed ML. Association of serum bicarbonate levels with gait speed and quadriceps strength in older adults. Am J Kidney Dis 2011;58:29–38. https://doi.org/10.1053/j.ajkd.2010.12.021 doi: 10.1053/j.ajkd.2010.12.021. [DOI] [PMC free article] [PubMed]
  15. Yenchek R, Ix JH, Rifkin DE, Shlipak MG, Sarnak MJ, Garcia M, et al. Association of serum bicarbonate with incident functional limitation in older adults. Clin J Am Soc Nephrol 2014;9:2111–16. https://doi.org/10.2215/CJN.05480614 doi: 10.2215/CJN.05480614. [DOI] [PMC free article] [PubMed]
  16. Bailey JL, Wang X, England BK, Price SR, Ding X, Mitch WE. The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway. J Clin Invest 1996;97:1447–53. https://doi.org/10.1172/JCI118566 doi: 10.1172/JCI118566. [DOI] [PMC free article] [PubMed]
  17. Martin KJ, González EA. Metabolic bone disease in chronic kidney disease. J Am Soc Nephrol 2007;18:875–85. https://doi.org/10.1681/ASN.2006070771 doi: 10.1681/ASN.2006070771. [DOI] [PubMed]
  18. Chen W, Melamed ML, Abramowitz MK. Serum bicarbonate and bone mineral density in US adults. Am J Kidney Dis 2015;65:240–8. https://doi.org/10.1053/j.ajkd.2014.07.007 doi: 10.1053/j.ajkd.2014.07.007. [DOI] [PMC free article] [PubMed]
  19. Kato A, Kido R, Onishi Y, Kurita N, Fukagawa M, Akizawa T, et al. Association of serum bicarbonate with bone fractures in hemodialysis patients: the mineral and bone disorder outcomes study for Japanese CKD category 5D patients (MBD-5D). Nephron Clin Pract 2014;128:79–87. https://doi.org/10.1159/000365089 doi: 10.1159/000365089. [DOI] [PubMed]
  20. Grzegorzewska AE, Młot-Michalska M. Predictors of bone mineral density in dialyzed and non-dialyzed patients with chronic kidney disease. Adv Perit Dial 2010;26:116–24. [PubMed]
  21. Hu MK, Soiza RL, Witham MD. Oral bicarbonate therapy in chronic kidney disease: a systematic review and meta-analysis of randomised controlled trial. J Clin Med 2019; in press. https://doi.org/10.3390/jcm8020208 doi: 10.3390/jcm8020208. [DOI] [PMC free article] [PubMed]
  22. Mathur RP, Dash SC, Gupta N, Prakash S, Saxena S, Bhowmik D. Effects of correction of metabolic acidosis on blood urea and bone metabolism in patients with mild to moderate chronic kidney disease: a prospective randomized single blind controlled trial. Ren Fail 2006;28:1–5. https://doi.org/10.1080/08860220500461187 doi: 10.1080/08860220500461187. [DOI] [PubMed]
  23. de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 2009;20:2075–84. https://doi.org/10.1681/ASN.2008111205 doi: 10.1681/ASN.2008111205. [DOI] [PMC free article] [PubMed]
  24. Mahajan A, Simoni J, Sheather SJ, Broglio KR, Rajab MH, Wesson DE. Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy. Kidney Int 2010;78:303–9. https://doi.org/10.1038/ki.2010.129 doi: 10.1038/ki.2010.129. [DOI] [PubMed]
  25. Goraya N, Simoni J, Jo CH, Wesson DE. Treatment of metabolic acidosis in patients with stage 3 chronic kidney disease with fruits and vegetables or oral bicarbonate reduces urine angiotensinogen and preserves glomerular filtration rate. Kidney Int 2014;86:1031–8. https://doi.org/10.1038/ki.2014.83 doi: 10.1038/ki.2014.83. [DOI] [PubMed]
  26. Jeong J, Kwon SK, Kim HY. Effect of bicarbonate supplementation on renal function and nutritional indices in predialysis advanced chronic kidney disease. Electrolyte Blood Press 2014;12:80–7. https://doi.org/10.5049/EBP.2014.12.2.80 doi: 10.5049/EBP.2014.12.2.80. [DOI] [PMC free article] [PubMed]
  27. Bellasi A, Di Micco L, Santoro D, Marzocco S, De Simone E, Cozzolino M, et al. Correction of metabolic acidosis improves insulin resistance in chronic kidney disease. BMC Nephrol 2016;17:158. https://doi.org/10.1186/s12882-016-0372-x doi: 10.1186/s12882-016-0372-x. [DOI] [PMC free article] [PubMed]
  28. Dubey AK, Sahoo J, Vairappan B, Haridasan S, Parameswaran S, Priyamvada PS. Correction of metabolic acidosis improves muscle mass and renal function in chronic kidney disease stages 3 and 4: a randomized controlled trial [published online ahead of print 24 July 2018]. Nephrol Dial Transplant 2018. https://doi.org/10.1093/ndt/gfy214 doi: 10.1093/ndt/gfy214. [DOI] [PubMed]
  29. Kraut JA, Kurtz I. Metabolic acidosis of CKD: diagnosis, clinical characteristics, and treatment. Am J Kidney Dis 2005;45:978–93. https://doi.org/10.1053/j.ajkd.2005.03.003 doi: 10.1053/j.ajkd.2005.03.003. [DOI] [PubMed]
  30. Melzer D, Tavakoly B, Winder RE, Masoli JA, Henley WE, Ble A, Richards SH. Much more medicine for the oldest old: trends in UK electronic clinical records. Age Ageing 2015;44:46–53. https://doi.org/10.1093/ageing/afu113 doi: 10.1093/ageing/afu113. [DOI] [PMC free article] [PubMed]
  31. KDIGO 2012. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppls 2013;3:1–50. doi: 10.1038/ki.2013.243. [DOI] [PubMed]
  32. National Institute for Health and Care Excellence (NICE). Chronic Kidney Disease in Adults: Assessment and Management. Clinical guideline CG182. London: NICE; 2015. URL: www.nice.org.uk/guidance/cg182 (accessed 6 January 2019). [PubMed]
  33. Beaudart C, Zaaria M, Pasleau F, Reginster JY, Bruyère O. Health outcomes of sarcopenia: a systematic review and meta-analysis. PLOS ONE 2017;12:e0169548. https://doi.org/10.1371/journal.pone.0169548 doi: 10.1371/journal.pone.0169548. [DOI] [PMC free article] [PubMed]
  34. Kerr M. Chronic Kidney Disease in England: The Human and Financial Cost. NHS England; 2012. URL: www.england.nhs.uk/improvement-hub/wp-content/uploads/sites/44/2017/11/Chronic-Kidney-Disease-in-England-The-Human-and-Financial-Cost.pdf (accessed 11 January 2019).
  35. Witham MD, Band MM, Littleford RC, Avenell A, Soiza RL, McMurdo ME, et al. Does oral sodium bicarbonate therapy improve function and quality of life in older patients with chronic kidney disease and low-grade acidosis (the BiCARB trial)? Study protocol for a randomized controlled trial. Trials 2015;16:326. https://doi.org/10.1186/s13063-015-0843-6 doi: 10.1186/s13063-015-0843-6. [DOI] [PMC free article] [PubMed]
  36. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461–70. https://doi.org/10.7326/0003-4819-130-6-199903160-00002 doi: 10.7326/0003-4819-130-6-199903160-00002. [DOI] [PubMed]
  37. Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol 1994;49:M85–94. https://doi.org/10.1093/geronj/49.2.m85 doi: 10.1093/geronj/49.2.m85. [DOI] [PubMed]
  38. Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med 1995;332:556–61. https://doi.org/10.1056/NEJM199503023320902 doi: 10.1056/NEJM199503023320902. [DOI] [PMC free article] [PubMed]
  39. Wennie Huang WN, Perera S, VanSwearingen J, Studenski S. Performance measures predict onset of activity of daily living difficulty in community-dwelling older adults. J Am Geriatr Soc 2010;58:844–52. https://doi.org/10.1111/j.1532-5415.2010.02820.x doi: 10.1111/j.1532-5415.2010.02820.x. [DOI] [PMC free article] [PubMed]
  40. Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW, Berman LB. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985;132:919–23. [PMC free article] [PubMed]
  41. Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddall H, Cooper C, Sayer AA. A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing 2011;40:423–9. https://doi.org/10.1093/ageing/afr051 doi: 10.1093/ageing/afr051. [DOI] [PubMed]
  42. Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, Cuppari L, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 2008;73:391–8. https://doi.org/10.1038/sj.ki.5002585 doi: 10.1038/sj.ki.5002585. [DOI] [PubMed]
  43. EuroQol Group. EuroQol – a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199–208. https://doi.org/10.1016/0168-8510(90)90421-9 doi: 10.1016/0168-8510(90)90421-9. [DOI] [PubMed]
  44. Hays RD, Kallich JD, Mapes DL, Coons SJ, Carter WB. Development of the kidney disease quality of life (KDQOL) instrument. Qual Life Res 1994;3:329–38. https://doi.org/10.1007/BF00451725 doi: 10.1007/BF00451725. [DOI] [PubMed]
  45. Flynn TN, Chan P, Coast J, Peters TJ. Assessing quality of life among British older people using the ICEPOP CAPability (ICECAP-O) measure. Appl Health Econ Health Policy 2011;9:317–29. https://doi.org/10.2165/11594150-000000000-00000 doi: 10.2165/11594150-000000000-00000. [DOI] [PubMed]
  46. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 2005;14:1523–32. https://doi.org/10.1007/s11136-004-7713-0 doi: 10.1007/s11136-004-7713-0. [DOI] [PubMed]
  47. Burton LA, Sumukadas D, Witham MD, Struthers AD, McMurdo ME. Effect of spironolactone on physical performance in older people with self-reported physical disability. Am J Med 2013;126:590–7. https://doi.org/10.1016/j.amjmed.2012.11.032 doi: 10.1016/j.amjmed.2012.11.032. [DOI] [PMC free article] [PubMed]
  48. Sumukadas D, Witham MD, Struthers AD, McMurdo ME. Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial. CMAJ 2007;177:867–74. https://doi.org/10.1503/cmaj.061339 doi: 10.1503/cmaj.061339. [DOI] [PMC free article] [PubMed]
  49. Witham MD, Price RJ, Struthers AD, Donnan PT, Messow CM, Ford I, McMurdo ME. Cholecalciferol treatment to reduce blood pressure in older patients with isolated systolic hypertension: the VitDISH randomized controlled trial. JAMA Intern Med 2013;173:1672–9. https://doi.org/10.1001/jamainternmed.2013.9043 doi: 10.1001/jamainternmed.2013.9043. [DOI] [PubMed]
  50. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327–40. https://doi.org/10.1002/(SICI)1099-1050(199707)6:4<327::AID-HEC282>3.0.CO;2-W doi: 10.1002/(SICI)1099-1050(199707)6:4&#x0003c;327::AID-HEC282&#x0003e;3.0.CO;2-W. [DOI] [PubMed]
  51. van Hout BA, Al MJ, Gordon GS, Rutten FF. Costs, effects and the C/E ratios alongside a clinical trial. Health Econ 1994;3:309–19. https://doi.org/10.1002/hec.4730030505 doi: 10.1002/hec.4730030505. [DOI] [PubMed]
  52. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLOS Med 2010;7:e1000251. https://doi.org/10.1371/journal.pmed.1000251 doi: 10.1371/journal.pmed.1000251. [DOI] [PMC free article] [PubMed]
  53. Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in common physical performance measures in older adults. J Am Geriatr Soc 2006;54:743–9. https://doi.org/10.1111/j.1532-5415.2006.00701.x doi: 10.1111/j.1532-5415.2006.00701.x. [DOI] [PubMed]
  54. Christensen PM, Shirai Y, Ritz C, Nordsborg NB. Caffeine and bicarbonate for speed: a meta-analysis of legal supplements potential for improving intense endurance exercise performance. Front Physiol 2017;8:240. https://doi.org/10.3389/fphys.2017.00240 doi: 10.3389/fphys.2017.00240. [DOI] [PMC free article] [PubMed]
  55. Melamed ML, Horwitz EJ, Dobre MA, Abramowitz MK, Lo Y, Hostetter TH. The Effects of Sodium Bicarbonate in CKD Categories 3 and 4: A Randomized, Placebo-controlled, Multi-center Clinical Trial. American Society of Nephrology Kidney Week, San Diego, CA, USA, 23–28 October 2018. Abstract SA-OR037.
  56. Di Iorio B, Aucella F, Conte G, Cupisti A, Santoro D. A prospective, multicenter, randomized, controlled study: the correction of metabolic acidosis with use of bicarbonate in Chronic Renal Insufficiency (UBI) study. J Nephrol 2012;25:437–40. https://doi.org/10.5301/jn.5000014 doi: 10.5301/jn.5000014. [DOI] [PubMed]
  57. Gaggl M, Cejka D, Plischke M, Heinze G, Fraunschiel M, Schmidt A, et al. Effect of oral sodium bicarbonate supplementation on progression of chronic kidney disease in patients with chronic metabolic acidosis: study protocol for a randomized controlled trial (SoBic-Study). Trials 2013;14:196. https://doi.org/10.1186/1745-6215-14-196 doi: 10.1186/1745-6215-14-196. [DOI] [PMC free article] [PubMed]
  58. Witham MD, Stott DJ. Conducting and reporting trials for older people. Age Ageing 2017;46:889–94. https://doi.org/10.1093/ageing/afx153 doi: 10.1093/ageing/afx153. [DOI] [PubMed]
  59. Department of Health and Social Care (DHSC). NHS Reference Costs 2016–17. London: DHSC; 2017. URL: https://improvement.nhs.uk/documents/3479/201617_ReferenceCostData.zip
  60. Curtis L, Burns A. Unit Costs of Health and Social Care 2017. Canterbury: PSSRU, University of Kent; 2017.
  61. National Institute for Health and Care Excellence (NICE). Home Care for Older People. Quality standard QS123. London: NICE; 2016. URL: www.nice.org.uk/guidance/qs123 (accessed 19 January 2019).

RESOURCES